Pancreatic Cancer Clinical Trial
Official title:
Randomized Controlled Trial of Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient Controlled Analgesia (3:1) in Patients Undergoing Liver and/or Pancreatic Resection
The goal of this clinical research study is to learn if there is a difference in patients'
quality of recovery if they receive 1 of 2 standard kinds of pain control treatments after
surgery on the liver and/or pancreas. Researchers want to learn which method helps people to
recover more completely and more quickly after surgery.
The 2 kinds of pain control are intravenous (IV) pain management and epidural pain
management.
Study Groups:
If you agree to take part in this study, you will be randomly assigned (as in the flip of a
coin) to 1 of 2 groups. For every participant assigned to Group 1, 3 participants will be
assigned to Group 2. This means you are 3 times more likely to be assigned to Group 2 than
you are to Group 1.
- Group 1 will receive IV pain management.
- Group 2 will receive epidural pain management.
Group 1:
IV pain management will be given through a needle in your arm. This needle will be placed
when you are either in the holding area or in the operating room. You will have this needle
placed no matter if you take part in this study or not. The needle is used to give drugs and
manage fluids during surgery.
After surgery, your doctor will set the limit for the highest dose of pain medication that
you can receive at any time, but you will be able to use a hand-held button to adjust your
drug according to the level of pain you may be having.
If your pain is not well controlled, the study staff may decide you can be switched to Group
2 if it seems to be in your best interest.
Group 2:
Epidural pain management will be given through a needle inserted into the space between the
covering of your spinal cord and the cord itself. This area is full of fluid and is called
the epidural region. The needle will be placed before your surgery, either in the holding
area or in the operating room by the doctor that gives your anesthesia.
If your epidural does not work, the study staff may decide you can be switched to Group 1 if
it seems to be in your best interest.
Both Groups:
During your surgery, you will have a catheter (sterile flexible tube) placed in an artery.
This catheter will be used to provide additional fluid and blood support and to monitor you
during surgery. Your doctor will explain this procedure to you in more detail, and you will
be required to sign a separate consent form.
During surgery, blood (about 1 tablespoon) will be drawn before you receive anesthesia. This
blood will be drawn using one of the IV lines that you already have in place for your
surgery. This blood will be tested to look for certain proteins called cytokines that may
help researchers to understand how your body is responding to pain and how pain is affecting
the healing process.
You will be asked to sign a separate consent form that describes the surgery and its risks in
detail. The study staff will also tell you about the standard pain medications, how they will
be given, and the possible risks.
After Surgery:
After your surgery, you will go to the Post-Anesthesia Care Unit (PACU) for recovery. You
will have a physical exam to check your recovery. Your vital signs will also be measured. You
will be asked how you are feeling. Your doctor(s) will decide whether you will go from the
PACU to the intensive care unit (ICU), overnight recovery suite, or will be moved to a
regular post-surgical recovery floor room, where your recovery will be watched.
On Days 1, 3, and 5 after your surgery, blood (about 1 tablespoon) will be drawn for cytokine
testing. This blood will be drawn along with the other routine blood work that you will have
after your surgery.
If you are in Group 2, a member of the MD Anderson Pain Service will check your epidural site
every day to make sure that it is working and that there are no problems with the area around
your epidural. A nurse will also check during each shift (about every 8-10 hours) to see how
well you are able to move and how the epidural is affecting your feeling in the area it is
supposed to be working in.
In both groups, you will be asked to rate your level of pain management on a scale of 0-10.
When you first come out of surgery, this pain rating will happen about every hour. Your pain
will also be rated about every hour if you are assigned to the surgical ICU. When you get to
your room (overnight recovery or surgical floor), it will happen about every 4 hours. You can
use your call bell to let a nurse know if your pain is intolerable between the nurses checks.
Questionnaires:
Before your surgery, you will fill out questionnaires about the pain and your quality of
life. This should take about 20 minutes to complete.
From the day after surgery (Day 1) through Day 5, you will also be asked to fill out
questionnaires about your recovery and any side effects and symptoms you may be having from
the pain medication. This will take about 20-40 minutes.
While you are in the hospital, you will be asked to answer some questions that will measure
how quickly you recover from the sedation used during your surgery. Each shift (about every
8-10 hours), a nurse will ask you questions to find out how quickly you are recovering from
anesthesia.
Length of Study Participation:
The pain medication or epidural insertion will be stopped early if you are having intolerable
side effects or if the medication is not working.
Your participation in the study will be over after Day 5.
This is an investigational study. IV pain management and epidural pain management are FDA
approved and commercially available. Randomly assigning you to a type of pain management and
comparing the treatments is being done for research purposes only.
Up to 200 patients will be enrolled in this study. All will be enrolled at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|